Paper1136801
Proceedings: "First-pass" effect and dose dependent availability as factors contributing to interindividual differences in equilibrium concentrations of alprenolol in man.
Bahr C and 4 others. Acta Pharm Suec, 1974. Cited by 12 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Proceedings: "First-pass" effect and dose dependent availability as factors contributing to interindividual differences in equilibrium concentrations of alprenolol in man. Papers, record 1136801. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/1136801
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Proceedings: "First-pass" effect and dose dependent availability as factors contributing to interindividual differences in equilibrium concentrations of alprenolol in man.
- PubMed
Topics8
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Alprenolol | Major topic |
| Animals | |
| Dose-Response Relationship, Drug | |
| Half-Life | |
| Humans | |
| Kinetics | |
| Liver | |
| Rats |
Source PubMed
Cited by8
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 12 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 2,859,047 | Human pharmacokinetic and pharmacodynamic studies on Ro31-1118, a new beta-adrenoceptor antagonist. | Br J Clin Pharmacol | 1985 | https://conductscience.org/library/papers/2859047 | PubMed |
| 901,706 | Pindolol, a beta-adrenoceptor blocking agent with a negligible first-pass effect. | Br J Clin Pharmacol | 1977 | https://conductscience.org/library/papers/901706 | PubMed |
| 881,641 | Importance of "first-pass elimination" for interindividual differences in steady-state concentrations of the adrenergic beta-receptor antagonist alprenolol. | J Pharmacokinet Biopharm | 1977 | https://conductscience.org/library/papers/881641 | PubMed |
| 579,342 | Pharmacokinetics of tolamolol in the treatment of hypertension. | Eur J Clin Pharmacol | 1977 | https://conductscience.org/library/papers/579342 | PubMed |
| 346,288 | Individual differences in the disposition of drugs metabolised in the body. | Clin Pharmacokinet | 1978 | https://conductscience.org/library/papers/346288 | PubMed |
| 336,379 | Long term effect of timolol and hydrochlorothiazide, or hydrochlorothiazide and amiloride, in essential hypertension. | Eur J Clin Pharmacol | 1977 | https://conductscience.org/library/papers/336379 | PubMed |
| 13,958 | Clinical pharmacokinetics of beta-adrenoreceptor blocking drugs. | Clin Pharmacokinet | 1976 | https://conductscience.org/library/papers/13958 | PubMed |
| 9,292 | Pharmacokinetics and pharmacodynamics of alprenolol in the treatment of hypertension. I. Relationship between plasma concentration and adrenergic beta-receptor blockade. | Eur J Clin Pharmacol | 1976 | https://conductscience.org/library/papers/9292 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/1136801
GET https://conductscience.org/api/papers/v1/1136801/authors